About Bliss Gvs Pharma Limited
Data last updated: 09 January 2026
Bliss Gvs Pharma Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 11 December 1984, the company has been in operation for over 42 years.
Registered with ROC Mumbai under CIN L24230MH1984PLC034771. Listed on BSE: 506197 and NSE: BLISSGVS.
Capital: an authorised share capital of ₹15 Cr and a paid-up capital of ₹10.58 Cr. Formerly known as Bliss Gvs Phrma Limited (Cn) and Bliss Chemicals and Pharmaceuticals India Limited. It is led by directors including Vibha Gagan Sharma and Santosh Laxman Parab.
Last AGM: 31 July 2025. Financial statements filed for year ended 31 March 2025. Office: 102 Hyde Park Sakivihar Road Andheri (East)., Mumbai, Maharashtra, India – 400072.
As per the financials filed for FY 2025, the company reported a revenue of ₹846.22 Cr, a growth of 6% compared to the previous year.
The company has a workforce of approximately 926 employees as per the latest available data. Its group structure includes 1 subsidiary.
The company is associated with 1 brand - Bliss Gvs. As per MCA filings, the company has open charges of ₹261 Cr and satisfied charges of ₹301.25 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website blissgvs.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered Address102 Hyde Park Sakivihar Road Andheri (East)., Mumbai, Maharashtra, India – 400072
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Bliss Gvs Pharma Limited
Bliss Gvs Pharma Limited has undergone 3 name changes throughout its history. The company was previously known as Bliss Gvs Phrma Limited (Cn), Bliss Chemicals And Pharmaceuticals India Limited, and Bliss Gvs Phrma Limited (Cn). The current legal name is Bliss Gvs Pharma Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Bliss Gvs Pharma Limited | Current |
| Bliss Gvs Phrma Limited (Cn) | Previous |
| Bliss Chemicals And Pharmaceuticals India Limited | Previous |
| Bliss Gvs Phrma Limited (Cn) | Previous |
CIN History of Bliss Gvs Pharma Limited
Bliss Gvs Pharma Limited has one previous CIN (Corporate Identification Number): U24230MH1984PTC034771. The current CIN is L24230MH1984PLC034771, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230MH1984PLC034771 | Current |
| U24230MH1984PTC034771 | Previous |
Associated Brands with Bliss Gvs Pharma Limited
Bliss Gvs Pharma Limited operates one associated brand: Bliss GVS. These brands represent Bliss Gvs Pharma Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical products including suppositories and pessaries are manufactured. | blissgvs.com |
Business Activity of Bliss Gvs Pharma Limited
Bliss Gvs Pharma Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Bliss Gvs Pharma Limited
Bliss Gvs Pharma Limited is audited by Kalyaniwala & Mistry LLP (ICAI peer reviewed, certificate valid till 2027-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Kalyaniwala & Mistry LLP (ICAI peer reviewed, certificate valid till 2027-07-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Bliss Gvs Pharma Limited
Bliss Gvs Pharma Limited is currently managed by 8 directors, with 24 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vibha Gagan Sharma | Whole-Time Director | 29 Jul 2008 | 17 Years 11 Months | Current |
|
Santosh Laxman Parab
Also directs:
Bliss Gvs Pharma Limited, Camlin Fine Sciences Limited
|
Director | 24 May 2016 | 10 Years 1 Months | Current |
| Nandkumar Kashinath Chodankar | Director | 22 Jun 2024 | 2 Years 0 Months | Current |
| Shilpa Bhatia | Director | 11 Feb 2020 | 6 Years 4 Months | Current |
| Shruti Vishal Rao | Whole-Time Director | 27 Jul 2006 | 19 Years 11 Months | Current |
Financials of Bliss Gvs Pharma Limited FY 2026 filings available
Bliss Gvs Pharma Limited reported revenue of ₹927.11 Cr (up 14.5% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹927.11 Cr | ₹809.73 Cr | ₹770.24 Cr | ₹751.59 Cr | ₹747.45 Cr | ₹577.21 Cr | ₹689.31 Cr |
| Other Income | ₹73.53 Cr | ₹36.49 Cr | ₹28.74 Cr | ₹17.79 Cr | ₹31.49 Cr | ₹20.22 Cr | ₹37.12 Cr |
| Total Income | ₹1,000.64 Cr | ₹846.22 Cr | ₹798.98 Cr | ₹769.37 Cr | ₹778.95 Cr | ₹597.43 Cr | ₹726.43 Cr |
| Cost of Materials Consumed | ₹386.26 Cr | ₹372.51 Cr | ₹339.12 Cr | ₹330.04 Cr | ₹385.27 Cr | ₹259.81 Cr | ₹256.62 Cr |
| Purchases of Stock-in-Trade | ₹61.25 Cr | ₹49.29 Cr | ₹51.35 Cr | ₹44.34 Cr | ₹34.91 Cr | ₹80.98 Cr | ₹175.67 Cr |
| Changes in Inventories | -₹22.44 Cr | -₹8.11 Cr | -₹8.35 Cr | ₹26.94 Cr | -₹29.2 Cr | -₹11.88 Cr | ₹7.68 Cr |
| Employee Benefit Expense | ₹136.43 Cr | ₹112.05 Cr | ₹95.58 Cr | ₹86.17 Cr | ₹76.15 Cr | ₹68.09 Cr | ₹53.69 Cr |
| Finance Costs | ₹12.01 Cr | ₹8.12 Cr | ₹6.91 Cr | ₹10.36 Cr | ₹4.74 Cr | ₹5.51 Cr | ₹5.41 Cr |
| Depreciation & Amortisation | ₹33.48 Cr | ₹29.42 Cr | ₹26.38 Cr | ₹18.67 Cr | ₹17.33 Cr | ₹17.23 Cr | ₹12.59 Cr |
| Other Expenses | ₹201.58 Cr | ₹157.3 Cr | ₹141.92 Cr | ₹146.77 Cr | ₹161.98 Cr | ₹73.56 Cr | ₹72.42 Cr |
| Total Expenses | ₹808.57 Cr | ₹720.58 Cr | ₹652.91 Cr | ₹663.3 Cr | ₹651.19 Cr | ₹493.3 Cr | ₹584.08 Cr |
| Profit Before Exceptional Items & Tax | ₹192.08 Cr | ₹125.64 Cr | ₹146.07 Cr | ₹106.07 Cr | ₹127.76 Cr | ₹104.13 Cr | ₹142.35 Cr |
| Exceptional Items | -₹2.49 Cr | ₹0 | -₹29.2 Cr | ₹0 | -₹73.59 Cr | ₹0 | -₹13.38 Cr |
| Profit Before Tax | ₹189.59 Cr | ₹125.64 Cr | ₹116.87 Cr | ₹106.07 Cr | ₹54.17 Cr | ₹104.13 Cr | ₹128.97 Cr |
| Total Tax Expense | ₹54.86 Cr | ₹35.38 Cr | ₹35.29 Cr | ₹29.34 Cr | ₹31.04 Cr | ₹30.16 Cr | ₹33.71 Cr |
| Net Profit | ₹134.73 Cr | ₹90.26 Cr | ₹81.58 Cr | ₹76.73 Cr | ₹23.13 Cr | ₹73.97 Cr | ₹95.25 Cr |
| attributable to Owners | ₹129.13 Cr | ₹84.3 Cr | ₹75.45 Cr | ₹70.86 Cr | ₹15.04 Cr | ₹68.49 Cr | ₹97.27 Cr |
| attributable to NCI | ₹5.6 Cr | ₹5.96 Cr | ₹6.12 Cr | ₹5.88 Cr | ₹8.09 Cr | ₹5.84 Cr | -₹2.01 Cr |
| Other Comprehensive Income | ₹2.03 Cr | -₹2.35 Cr | ₹4.55 Cr | -₹6.38 Cr | -₹7.41 Cr | -₹51.29 Lakh | ₹3.67 Cr |
| Total Comprehensive Income | ₹136.76 Cr | ₹87.91 Cr | ₹86.13 Cr | ₹70.35 Cr | ₹15.72 Cr | ₹73.46 Cr | ₹98.92 Cr |
| EBITDA (computed) | ₹237.57 Cr | ₹163.18 Cr | ₹179.36 Cr | ₹135.11 Cr | ₹149.83 Cr | ₹126.87 Cr | ₹160.34 Cr |
| Basic EPS | ₹12.23 | ₹8.02 | ₹7.23 | ₹6.83 | ₹1.46 | ₹6.64 | ₹9.43 |
| Diluted EPS | ₹12.00 | ₹7.95 | ₹7.11 | ₹6.72 | ₹1.43 | ₹6.49 | ₹9.43 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹1,492.41 Cr | ₹1,300.84 Cr | ₹1,213.87 Cr | ₹1,156.85 Cr |
| Non-current Assets | ₹546.08 Cr | ₹474.33 Cr | ₹402.25 Cr | ₹459.49 Cr |
| Current Assets | ₹946.34 Cr | ₹819.33 Cr | ₹811.62 Cr | ₹697.37 Cr |
| Property, Plant & Equipment | ₹450.68 Cr | ₹397.01 Cr | ₹361.55 Cr | ₹370.11 Cr |
| Inventories | ₹150.73 Cr | ₹125.73 Cr | ₹118.45 Cr | ₹103.06 Cr |
| Trade Receivables | ₹517.19 Cr | ₹438.36 Cr | ₹404.35 Cr | ₹385.17 Cr |
| Cash & Equivalents | ₹35.14 Cr | ₹23.79 Cr | ₹23.14 Cr | ₹24.96 Cr |
| Equity (Net Worth) | ₹1,231.76 Cr | ₹1,091.85 Cr | ₹1,002.98 Cr | ₹917.42 Cr |
| Equity Share Capital | ₹10.58 Cr | ₹10.54 Cr | ₹10.47 Cr | ₹10.42 Cr |
| Borrowings (Non-current) | ₹0 | ₹19.85 Cr | ₹35.59 Cr | ₹40.69 Cr |
| Borrowings (Current) | ₹2.93 Cr | ₹51.13 Cr | ₹52.21 Cr | ₹57.38 Cr |
| Total Debt (computed) | ₹2.93 Cr | ₹70.97 Cr | ₹87.81 Cr | ₹98.07 Cr |
| Current Liabilities | ₹235.54 Cr | ₹171.72 Cr | ₹159.82 Cr | ₹193.26 Cr |
| Total Liabilities | ₹260.65 Cr | ₹208.99 Cr | ₹210.89 Cr | ₹239.43 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹138.72 Cr | ₹105.91 Cr | ₹152.45 Cr | ₹34.31 Cr | ₹135.48 Cr |
| Investing Cash Flow | -₹38.28 Cr | -₹75.44 Cr | -₹132.82 Cr | -₹7.75 Cr | -₹92.98 Cr |
| Financing Cash Flow | -₹89.21 Cr | -₹30.34 Cr | -₹20.89 Cr | -₹24.94 Cr | -₹23.73 Cr |
| Capital Expenditure | ₹56.83 Cr | ₹76.07 Cr | ₹28.33 Cr | ₹93.8 Cr | ₹0 |
| Free Cash Flow (computed) | ₹81.89 Cr | ₹29.85 Cr | ₹124.12 Cr | -₹59.49 Cr | ₹135.48 Cr |
| Dividends Paid | ₹10.74 Cr | ₹5.45 Cr | ₹5.39 Cr | ₹5.44 Cr | ₹5.33 Cr |
| Net Change in Cash | ₹11.32 Cr | ₹22.61 Lakh | -₹1.42 Cr | ₹3.02 Cr | ₹18.78 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹256.99 Cr | ₹218.25 Cr | ₹244.4 Cr | ₹207.47 Cr | ₹197.99 Cr | ₹210.42 Cr | ₹217.68 Cr | ₹183.64 Cr | ₹198.13 Cr | ₹200.72 Cr | ₹211.88 Cr | ₹159.52 Cr |
| Other Income | ₹11.16 Cr | ₹18.46 Cr | ₹20.18 Cr | ₹35.45 Cr | ₹12.07 Cr | ₹15.27 Cr | ₹5.04 Cr | ₹4.12 Cr | ₹5.6 Cr | ₹5.42 Cr | ₹12.6 Cr | ₹5.11 Cr |
| Total Income | ₹268.15 Cr | ₹236.71 Cr | ₹264.58 Cr | ₹242.92 Cr | ₹210.05 Cr | ₹225.68 Cr | ₹222.72 Cr | ₹187.77 Cr | ₹203.73 Cr | ₹206.14 Cr | ₹224.48 Cr | ₹164.63 Cr |
| Cost of Materials Consumed | ₹111.26 Cr | ₹86.22 Cr | ₹95.37 Cr | ₹93.41 Cr | ₹76.61 Cr | ₹97.41 Cr | ₹100.01 Cr | ₹98.48 Cr | ₹87.28 Cr | ₹90.97 Cr | ₹89.57 Cr | ₹71.29 Cr |
| Purchases of Stock-in-Trade | ₹18.21 Cr | ₹20.2 Cr | ₹2.26 Cr | ₹20.57 Cr | ₹13.53 Cr | ₹19.03 Cr | ₹11.82 Cr | ₹4.9 Cr | ₹7.98 Cr | ₹7.55 Cr | ₹13.04 Cr | ₹22.78 Cr |
| Changes in Inventories | -₹16.01 Cr | -₹4.76 Cr | ₹20.42 Cr | -₹22.1 Cr | ₹9.29 Cr | -₹2.25 Cr | ₹3.09 Cr | -₹18.24 Cr | ₹20.65 Lakh | ₹3.97 Cr | -₹2.88 Cr | -₹9.64 Cr |
| Employee Benefit Expense | ₹36.14 Cr | ₹35.94 Cr | ₹33.35 Cr | ₹31 Cr | ₹28.24 Cr | ₹29.76 Cr | ₹27.51 Cr | ₹26.54 Cr | ₹24.51 Cr | ₹24.29 Cr | ₹23.26 Cr | ₹23.52 Cr |
| Finance Costs | ₹2.01 Cr | ₹1.49 Cr | ₹3.04 Cr | ₹5.47 Cr | ₹1.68 Cr | ₹1.08 Cr | ₹3.83 Cr | ₹1.53 Cr | ₹1.85 Cr | ₹2.12 Cr | ₹1.45 Cr | ₹1.49 Cr |
| Depreciation & Amortisation | ₹8.67 Cr | ₹8.35 Cr | ₹8.26 Cr | ₹8.2 Cr | ₹8.04 Cr | ₹7.55 Cr | ₹6.98 Cr | ₹6.85 Cr | ₹6.85 Cr | ₹6.95 Cr | ₹6.39 Cr | ₹6.19 Cr |
| Other Expenses | ₹62.96 Cr | ₹45.86 Cr | ₹61.24 Cr | ₹43.25 Cr | ₹49.23 Cr | ₹36.67 Cr | ₹33.77 Cr | ₹37.63 Cr | ₹49.8 Cr | ₹30.25 Cr | ₹34.51 Cr | ₹27.36 Cr |
| Total Expenses | ₹223.23 Cr | ₹193.3 Cr | ₹223.94 Cr | ₹179.81 Cr | ₹186.61 Cr | ₹189.26 Cr | ₹187.01 Cr | ₹157.69 Cr | ₹178.48 Cr | ₹166.1 Cr | ₹165.35 Cr | ₹142.99 Cr |
| Profit Before Exceptional Items & Tax | ₹44.92 Cr | ₹43.41 Cr | ₹40.63 Cr | ₹63.11 Cr | ₹23.44 Cr | ₹36.42 Cr | ₹35.71 Cr | ₹30.07 Cr | ₹25.25 Cr | ₹40.04 Cr | ₹59.13 Cr | ₹21.65 Cr |
| Exceptional Items | ₹2.66 Lakh | -₹2.51 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹29.2 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹44.95 Cr | ₹40.9 Cr | ₹40.63 Cr | ₹63.11 Cr | ₹23.44 Cr | ₹36.42 Cr | ₹35.71 Cr | ₹30.07 Cr | -₹3.95 Cr | ₹40.04 Cr | ₹59.13 Cr | ₹21.65 Cr |
| Total Tax Expense | ₹7.95 Cr | ₹16.12 Cr | ₹12.04 Cr | ₹18.75 Cr | ₹6.79 Cr | ₹10.62 Cr | ₹10.01 Cr | ₹7.97 Cr | ₹96.49 Lakh | ₹10.97 Cr | ₹16.09 Cr | ₹7.27 Cr |
| Net Profit | ₹37 Cr | ₹24.78 Cr | ₹28.59 Cr | ₹44.36 Cr | ₹16.65 Cr | ₹25.8 Cr | ₹25.69 Cr | ₹22.11 Cr | -₹4.91 Cr | ₹29.07 Cr | ₹43.04 Cr | ₹14.37 Cr |
| attributable to Owners | ₹35.58 Cr | ₹23.27 Cr | ₹27.25 Cr | ₹43.04 Cr | ₹15.54 Cr | ₹23.8 Cr | ₹24.26 Cr | ₹20.7 Cr | -₹9.15 Cr | ₹27.61 Cr | ₹42.31 Cr | ₹14.69 Cr |
| attributable to NCI | ₹1.42 Cr | ₹1.51 Cr | ₹1.34 Cr | ₹1.32 Cr | ₹1.11 Cr | ₹2 Cr | ₹1.43 Cr | ₹1.41 Cr | ₹4.23 Cr | ₹1.46 Cr | ₹73.79 Lakh | -₹31.06 Lakh |
| Other Comprehensive Income | -₹2.4 Cr | ₹3.56 Cr | -₹4.98 Cr | ₹5.85 Cr | -₹48.82 Lakh | -₹9.4 Lakh | -₹1.8 Cr | ₹3.32 Lakh | ₹17.52 Cr | -₹1.67 Cr | -₹6.25 Cr | -₹5.05 Cr |
| Total Comprehensive Income | ₹34.6 Cr | ₹28.34 Cr | ₹23.61 Cr | ₹50.21 Cr | ₹16.16 Cr | ₹25.71 Cr | ₹23.9 Cr | ₹22.14 Cr | ₹12.61 Cr | ₹27.4 Cr | ₹36.79 Cr | ₹9.32 Cr |
| EBITDA (computed) | ₹55.6 Cr | ₹53.25 Cr | ₹51.94 Cr | ₹76.78 Cr | ₹33.15 Cr | ₹45.05 Cr | ₹46.51 Cr | ₹38.45 Cr | ₹33.95 Cr | ₹49.12 Cr | ₹66.97 Cr | ₹29.33 Cr |
| Basic EPS | ₹3.37 | ₹2.20 | ₹2.58 | ₹4.08 | ₹1.47 | ₹2.27 | ₹2.31 | ₹1.97 | ₹-0.88 | ₹2.64 | ₹4.06 | ₹1.41 |
| Diluted EPS | ₹3.28 | ₹2.14 | ₹2.54 | ₹4.04 | ₹1.46 | ₹2.27 | ₹2.29 | ₹1.93 | ₹-0.86 | ₹2.60 | ₹3.98 | ₹1.38 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹729.81 Cr | ₹667.2 Cr | ₹605.46 Cr | ₹598.34 Cr | ₹636.36 Cr | ₹465.51 Cr | ₹441.95 Cr |
| Other Income | ₹43.72 Cr | ₹36.22 Cr | ₹33.5 Cr | ₹50.77 Cr | ₹32.63 Cr | ₹17.68 Cr | ₹34.93 Cr |
| Total Income | ₹773.53 Cr | ₹703.42 Cr | ₹638.96 Cr | ₹649.11 Cr | ₹668.98 Cr | ₹483.2 Cr | ₹476.88 Cr |
| Cost of Materials Consumed | ₹360.46 Cr | ₹339.47 Cr | ₹305.83 Cr | ₹293.66 Cr | ₹350.83 Cr | ₹215.65 Cr | ₹216.31 Cr |
| Purchases of Stock-in-Trade | ₹7.79 Cr | ₹0 | ₹0 | ₹0 | ₹2.01 Cr | ₹46.5 Cr | ₹18.05 Cr |
| Changes in Inventories | -₹25.62 Cr | ₹6.63 Cr | -₹6.36 Cr | ₹21.24 Cr | -₹8.9 Cr | -₹8.85 Cr | ₹2.37 Cr |
| Employee Benefit Expense | ₹121.5 Cr | ₹99.42 Cr | ₹82.59 Cr | ₹72.54 Cr | ₹65.06 Cr | ₹58.61 Cr | ₹44.02 Cr |
| Finance Costs | ₹11.11 Cr | ₹6.58 Cr | ₹5.81 Cr | ₹10.06 Cr | ₹4.32 Cr | ₹4.19 Cr | ₹4.56 Cr |
| Depreciation & Amortisation | ₹31.02 Cr | ₹27.05 Cr | ₹23.52 Cr | ₹15.17 Cr | ₹13.85 Cr | ₹13.76 Cr | ₹8.83 Cr |
| Other Expenses | ₹131.64 Cr | ₹130.09 Cr | ₹116.23 Cr | ₹120.74 Cr | ₹118.16 Cr | ₹62.14 Cr | ₹61.04 Cr |
| Total Expenses | ₹637.91 Cr | ₹609.25 Cr | ₹527.62 Cr | ₹533.41 Cr | ₹545.33 Cr | ₹392.01 Cr | ₹355.17 Cr |
| Profit Before Exceptional Items & Tax | ₹135.62 Cr | ₹94.17 Cr | ₹111.34 Cr | ₹115.69 Cr | ₹123.66 Cr | ₹91.19 Cr | ₹121.71 Cr |
| Exceptional Items | -₹2.16 Cr | ₹0 | -₹41.09 Cr | ₹0 | ₹2.75 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹133.46 Cr | ₹94.17 Cr | ₹70.26 Cr | ₹115.69 Cr | ₹126.4 Cr | ₹91.19 Cr | ₹121.71 Cr |
| Total Tax Expense | ₹36.59 Cr | ₹25.2 Cr | ₹19.61 Cr | ₹30.21 Cr | ₹33.74 Cr | ₹23.69 Cr | ₹29.38 Cr |
| Net Profit | ₹96.87 Cr | ₹68.97 Cr | ₹50.64 Cr | ₹85.48 Cr | ₹92.66 Cr | ₹67.5 Cr | ₹92.33 Cr |
| Other Comprehensive Income | -₹17.96 Lakh | -₹55.72 Lakh | -₹15.36 Lakh | -₹66.62 Lakh | ₹30.27 Lakh | ₹52.4 Lakh | -₹25.65 Lakh |
| Total Comprehensive Income | ₹96.69 Cr | ₹68.41 Cr | ₹50.49 Cr | ₹84.81 Cr | ₹92.97 Cr | ₹68.02 Cr | ₹92.08 Cr |
| EBITDA (computed) | ₹177.75 Cr | ₹127.8 Cr | ₹140.67 Cr | ₹140.92 Cr | ₹141.83 Cr | ₹109.14 Cr | ₹135.1 Cr |
| Basic EPS | ₹9.17 | ₹6.56 | ₹4.85 | ₹8.23 | ₹8.97 | ₹6.54 | ₹8.95 |
| Diluted EPS | ₹9.00 | ₹6.50 | ₹4.77 | ₹8.10 | ₹8.81 | ₹6.40 | ₹8.95 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹1,344.18 Cr | ₹1,219.7 Cr | ₹1,152.55 Cr | ₹1,139.69 Cr |
| Non-current Assets | ₹517.82 Cr | ₹452.01 Cr | ₹379.57 Cr | ₹410.04 Cr |
| Current Assets | ₹826.36 Cr | ₹767.69 Cr | ₹772.98 Cr | ₹729.65 Cr |
| Property, Plant & Equipment | ₹419.34 Cr | ₹367.66 Cr | ₹329.86 Cr | ₹324.61 Cr |
| Inventories | ₹110.92 Cr | ₹81.94 Cr | ₹89.45 Cr | ₹74.15 Cr |
| Trade Receivables | ₹457.12 Cr | ₹428.25 Cr | ₹399.51 Cr | ₹399.06 Cr |
| Cash & Equivalents | ₹3.33 Cr | ₹6.83 Cr | ₹13.87 Cr | ₹18.65 Cr |
| Equity (Net Worth) | ₹1,155.19 Cr | ₹1,058.63 Cr | ₹988.44 Cr | ₹937 Cr |
| Equity Share Capital | ₹10.58 Cr | ₹10.54 Cr | ₹10.47 Cr | ₹10.42 Cr |
| Borrowings (Non-current) | ₹0 | ₹19.67 Cr | ₹35.1 Cr | ₹40.69 Cr |
| Borrowings (Current) | ₹0 | ₹31.34 Cr | ₹30.54 Cr | ₹36.39 Cr |
| Total Debt (computed) | ₹0 | ₹51.01 Cr | ₹65.63 Cr | ₹77.08 Cr |
| Current Liabilities | ₹168.59 Cr | ₹124.55 Cr | ₹117.31 Cr | ₹153.36 Cr |
| Total Liabilities | ₹188.99 Cr | ₹161.06 Cr | ₹164.11 Cr | ₹202.69 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹123.16 Cr | ₹97.21 Cr | ₹125.92 Cr | ₹43.81 Cr | ₹114.05 Cr |
| Investing Cash Flow | -₹51.4 Cr | -₹77.73 Cr | -₹109.59 Cr | -₹12.97 Cr | -₹92.28 Cr |
| Financing Cash Flow | -₹75.37 Cr | -₹26.71 Cr | -₹20.76 Cr | -₹26.05 Cr | -₹12.62 Cr |
| Capital Expenditure | ₹59.55 Cr | ₹68.5 Cr | ₹38.68 Cr | ₹94.29 Cr | ₹73.67 Cr |
| Free Cash Flow (computed) | ₹63.61 Cr | ₹28.7 Cr | ₹87.25 Cr | -₹50.48 Cr | ₹40.38 Cr |
| Dividends Paid | ₹10.64 Cr | ₹5.39 Cr | ₹5.34 Cr | ₹5.38 Cr | ₹5.27 Cr |
| Net Change in Cash | -₹3.52 Cr | -₹7.23 Cr | -₹4.43 Cr | ₹4.79 Cr | ₹9.14 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q4 FY23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹211.54 Cr | ₹164.68 Cr | ₹190.23 Cr | ₹163.36 Cr | ₹156 Cr | ₹179.59 Cr | ₹182.65 Cr | ₹148.96 Cr | ₹163.82 Cr | ₹161.33 Cr | ₹171.32 Cr | ₹143.42 Cr |
| Other Income | ₹9.3 Cr | ₹10.23 Cr | ₹25.84 Cr | ₹10.59 Cr | ₹9.36 Cr | ₹11.66 Cr | ₹8.35 Cr | ₹6.84 Cr | ₹8.46 Cr | ₹7.9 Cr | ₹10.61 Cr | ₹6.48 Cr |
| Total Income | ₹220.84 Cr | ₹174.91 Cr | ₹216.07 Cr | ₹173.96 Cr | ₹165.36 Cr | ₹191.25 Cr | ₹191 Cr | ₹155.8 Cr | ₹172.28 Cr | ₹169.23 Cr | ₹181.93 Cr | ₹149.9 Cr |
| Cost of Materials Consumed | ₹102.28 Cr | ₹79.38 Cr | ₹89.96 Cr | ₹88.85 Cr | ₹68.79 Cr | ₹88.18 Cr | ₹91.41 Cr | ₹91.1 Cr | ₹78.5 Cr | ₹80.6 Cr | ₹83.56 Cr | ₹66.87 Cr |
| Purchases of Stock-in-Trade | ₹7.79 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹12.65 Cr | -₹1.03 Cr | ₹5.26 Cr | -₹17.21 Cr | ₹9.19 Cr | ₹8.04 Cr | ₹9.33 Cr | -₹19.92 Cr | ₹87.34 Lakh | ₹5.26 Cr | -₹5.27 Cr | ₹12.1 Cr |
| Employee Benefit Expense | ₹31.83 Cr | ₹31.81 Cr | ₹29.76 Cr | ₹28.1 Cr | ₹25.22 Cr | ₹26.3 Cr | ₹24.38 Cr | ₹23.52 Cr | ₹20.88 Cr | ₹20.97 Cr | ₹20.4 Cr | ₹18.87 Cr |
| Finance Costs | ₹1.81 Cr | ₹1.48 Cr | ₹2.71 Cr | ₹5.11 Cr | ₹1.3 Cr | ₹66.83 Lakh | ₹3.45 Cr | ₹1.17 Cr | ₹1.53 Cr | ₹1.79 Cr | ₹1.18 Cr | ₹4.97 Cr |
| Depreciation & Amortisation | ₹7.84 Cr | ₹7.8 Cr | ₹7.69 Cr | ₹7.68 Cr | ₹7.43 Cr | ₹6.96 Cr | ₹6.39 Cr | ₹6.26 Cr | ₹6.23 Cr | ₹6.25 Cr | ₹5.68 Cr | ₹3.97 Cr |
| Other Expenses | ₹38.14 Cr | ₹27.67 Cr | ₹47.23 Cr | ₹30.85 Cr | ₹39.07 Cr | ₹31.34 Cr | ₹32.15 Cr | ₹27.53 Cr | ₹38.41 Cr | ₹25.85 Cr | ₹30.31 Cr | ₹34.67 Cr |
| Total Expenses | ₹177.04 Cr | ₹147.11 Cr | ₹182.61 Cr | ₹143.39 Cr | ₹151.01 Cr | ₹161.48 Cr | ₹167.11 Cr | ₹129.65 Cr | ₹146.43 Cr | ₹140.71 Cr | ₹135.86 Cr | ₹141.45 Cr |
| Profit Before Exceptional Items & Tax | ₹43.8 Cr | ₹27.8 Cr | ₹33.46 Cr | ₹30.56 Cr | ₹14.36 Cr | ₹29.77 Cr | ₹23.89 Cr | ₹26.15 Cr | ₹25.85 Cr | ₹28.52 Cr | ₹46.07 Cr | ₹8.44 Cr |
| Exceptional Items | ₹35.82 Lakh | -₹2.51 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹41.09 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹44.15 Cr | ₹25.29 Cr | ₹33.46 Cr | ₹30.56 Cr | ₹14.36 Cr | ₹29.77 Cr | ₹23.89 Cr | ₹26.15 Cr | -₹15.23 Cr | ₹28.52 Cr | ₹46.07 Cr | ₹8.44 Cr |
| Total Tax Expense | ₹11.73 Cr | ₹6.68 Cr | ₹8.66 Cr | ₹9.51 Cr | ₹2.9 Cr | ₹8.72 Cr | ₹6.85 Cr | ₹6.73 Cr | -₹3.77 Cr | ₹7.8 Cr | ₹12.18 Cr | ₹2.34 Cr |
| Net Profit | ₹32.42 Cr | ₹18.61 Cr | ₹24.79 Cr | ₹21.05 Cr | ₹11.45 Cr | ₹21.05 Cr | ₹17.04 Cr | ₹19.42 Cr | -₹11.46 Cr | ₹20.72 Cr | ₹33.89 Cr | ₹6.11 Cr |
| Other Comprehensive Income | ₹5.08 Lakh | -₹17.08 Lakh | ₹3.57 Lakh | -₹9.53 Lakh | -₹14.28 Lakh | -₹11.58 Lakh | -₹17.11 Lakh | -₹12.75 Lakh | ₹53,000 | -₹10.13 Lakh | ₹1.88 Lakh | -₹9.14 Lakh |
| Total Comprehensive Income | ₹32.47 Cr | ₹18.44 Cr | ₹24.83 Cr | ₹20.96 Cr | ₹11.31 Cr | ₹20.94 Cr | ₹16.87 Cr | ₹19.29 Cr | -₹11.46 Cr | ₹20.62 Cr | ₹33.91 Cr | ₹6.02 Cr |
| EBITDA (computed) | ₹53.45 Cr | ₹37.08 Cr | ₹43.86 Cr | ₹43.36 Cr | ₹23.09 Cr | ₹37.4 Cr | ₹33.73 Cr | ₹33.58 Cr | ₹33.61 Cr | ₹36.56 Cr | ₹52.92 Cr | ₹17.39 Cr |
| Basic EPS | ₹3.06 | ₹1.76 | ₹2.35 | ₹2.00 | ₹1.08 | ₹2.00 | ₹1.63 | ₹1.85 | ₹-1.11 | ₹1.99 | ₹3.25 | ₹0.60 |
| Diluted EPS | ₹2.99 | ₹1.72 | ₹2.31 | ₹1.98 | ₹1.07 | ₹2.00 | ₹1.62 | ₹1.81 | ₹-1.08 | ₹1.95 | ₹3.19 | ₹0.59 |
Shareholding Pattern of Bliss Gvs Pharma Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 35.36%, foreign institutional investors hold 10.45%, domestic institutional investors hold 5.04%, retail and other public shareholders hold 49.15% of Bliss Gvs Pharma Limited. The company had 44,874 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 35.36% | 35.36% | 35.39% | 35.44% | 35.29% | 35.10% |
| Public | 64.64% | 64.64% | 64.61% | 64.56% | 64.71% | 64.90% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 35.36% | 35.29% | 34.97% | 35.04% | 33.14% | 33.31% | 41.60% | 41.60% | 60.16% | 60.16% | 60.16% |
| Public | 64.64% | 64.71% | 65.03% | 64.96% | 66.86% | 66.69% | 58.40% | 58.40% | 39.84% | 39.84% | 39.84% |
| Promoter change (YoY, %pts) | +0.07 | +0.32 | -0.07 | +1.90 | -0.17 | -8.29 | +0.00 | -18.56 | +0.00 | +0.00 | - |
Board & Governance of Bliss Gvs Pharma Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Bliss Gvs Pharma Limited has 6 directors - 3 independent and 3 executive. The board is chaired by Nandkumar Kashinath Chodankar.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Nandkumar Kashinath Chodankar | Non-Executive - Independent Director · Chairperson | 2024-06-22 | 1 |
| Santosh Laxman Parab | Non-Executive - Independent Director | 2016-05-24 | 1 |
| Narsimha Shibroor Kamath | Executive Director · CEO-MD | 2026-01-29 | 1 |
| Shilpa Vinodkumar Bhatia | Non-Executive - Independent Director | 2020-02-11 | 3 |
| Shruti Vishal Rao | Executive Director | 2006-07-27 | 1 |
| Vibha Gagan Sharman | Executive Director | 2008-07-29 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | Santosh Laxman Parab (Chairperson), Nandkumar Kashinath Chodankar, Shilpa Vinodkumar Bhatia, Narsimha Shibroor Kamath |
| Nomination and remuneration committee | Santosh Laxman Parab (Chairperson), Nandkumar Kashinath Chodankar, Shilpa Vinodkumar Bhatia |
| Stakeholders Relationship Committee | Nandkumar Kashinath Chodankar (Chairperson), Vibha Gagan Sharman, Shruti Vishal Rao, Shilpa Vinodkumar Bhatia, Narsimha Shibroor Kamath |
| Risk Management Committee | Shilpa Vinodkumar Bhatia (Chairperson), Shruti Vishal Rao, Narsimha Shibroor Kamath, Sourya Das, Deepak Sawant |
| Corporate Social Responsibility Committee | Nandkumar Kashinath Chodankar (Chairperson), Shruti Vishal Rao, Narsimha Shibroor Kamath, Shilpa Vinodkumar Bhatia |
Group Structure of Bliss Gvs Pharma Limited
Bliss Gvs Pharma Limited has 1 subsidiary company. This group structure data is as of FY 2023. The corporate group structure reflects Bliss Gvs Pharma Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Kremoint Pharma Pvt. Ltd. | U24230MH1992PTC066737 | - |
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Bliss Gvs Pharma Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Dec 2023 | Others | ₹35 Cr | Open |
| 02 Sep 2023 | Others | ₹75 Cr | Open |
| 17 Sep 2021 | Others | ₹65 Cr | Open |
| 21 Nov 2020 | Hdfc Bank Limited | ₹1 Cr | Open |
| 07 Oct 2006 | Others | ₹85 Cr | Open |
Total charge records: 23 View all charges
Employees and EPFO Compliance at Bliss Gvs Pharma Limited
Bliss Gvs Pharma Limited has a workforce of 926 employees as of Mar 31, 2025.
Employee Count & EPFO Data of Bliss Gvs Pharma Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Bliss Gvs Pharma Limited
GSTIN & GST Filing Data of Bliss Gvs Pharma Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Bliss Gvs Pharma Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Bliss Gvs Pharma Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Bliss Gvs Pharma Limited
MSME Payment Delays by Bliss Gvs Pharma Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Bliss Gvs Pharma Limited
Subsidiaries & Group Companies of Bliss Gvs Pharma Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Bliss Gvs Pharma Limited with ownership details.
MCA Filings & Documents of Bliss Gvs Pharma Limited
MCA Filings & Documents of Bliss Gvs Pharma Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Bliss Gvs Pharma Limited
Recent News on Bliss Gvs Pharma Limited
Frequently Asked Questions about Bliss Gvs Pharma Limited
Bliss Gvs Pharma Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 11 December 1984 (42+ years old) and is registered under CIN L24230MH1984PLC034771. Listed on BSE: 506197 and NSE: BLISSGVS. The company has 926 employees.
Bliss Gvs Pharma Limited reported revenue of ₹846.22 Cr for FY 2025 (up 6.00% YoY).
The current directors of Bliss Gvs Pharma Limited are:
- Vibha Gagan Sharma
- Santosh Laxman Parab
- Nandkumar Kashinath Chodankar
- Deepak Bhalchandra Sawant
- Shilpa Bhatia
- Shruti Vishal Rao
- Aditi Himanshu Bhatt
- Narsimha Shibroor Kamath
The primary industry of Bliss Gvs Pharma Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Bliss Gvs Pharma Limited is listed on both BSE (code: 506197) and NSE (symbol: BLISSGVS).
Bliss Gvs Pharma Limited can be reached at the registered office: 102 Hyde Park Sakivihar Road Andheri East, Mumbai, Maharashtra, India – 400072, or through the website blissgvs.com.